US FDA panel to review expanded use of Merck AstraZeneca's cancer drug

US FDA panel to review expanded use of Merck AstraZeneca's cancer drug The companies' are seeking approval of the drug Lynparza in combination with other medications - biraterone and prednisone or prednisolone -for the treatment of a type of treatment-resistant prostate cancer in adult patients. https://ift.tt/L0NPsBH